Leaders

Women leaders in the healthcare industry are playing a transformative role in redefining modern medicine through innovation, accessibility, and compassionate leadership. Across specialized sectors such as oncology, diagnostics, biotechnology, and precision medicine, women entrepreneurs and medical professionals are building institutions that not only advance healthcare technology but also make quality treatment more patient-centric and accessible.

Their leadership is helping bridge critical healthcare gaps, especially in underserved regions, where access to advanced medical services remains limited. One such inspiring leader is Parveen Kundu, Founder of RNM Theranostic Center.

With a strong academic foundation from All India Institute of Medical Sciences, where she completed both her graduation and post-graduation, Parveen Kundu developed a deep understanding of ethical and quality-driven healthcare. Her senior residency at Postgraduate Institute of Medical Education and Research further strengthened her leadership skills and gave her exposure to advanced department-building practices in nuclear medicine.

In 2020, despite the challenges posed by the COVID-19 pandemic and the capital-intensive nature of the field, she established RNM Theranostic Center. Today, RNM stands among India’s pioneering woman- led standalone theranostic centers, delivering advanced diagnostics, radionuclide therapies, and personalized oncology care with a strong focus on ethics, affordability, and accessibility. Let’s read.

RNM Theranostic Center is making a significant impact in precision oncology. How are you transforming cancer diagnosis and treatment through advanced theranostic care?

At RNM, I focus on providing precise and timely cancer diagnosis through advanced PET-CT imaging and theranostic solutions. I believe nuclear medicine plays a critical role throughout the patient’s oncology journey, from diagnosis and staging to therapy assessment and palliative care. One major challenge in India is delayed access to advanced diagnostics, especially in smaller cities. Through targeted radionuclide therapies such as Lu-177 PSMA, DOTATATE therapy, and radioiodine treatment, we are bringing world-class oncology care closer to patients. My goal has always been to make advanced cancer treatment more accessible, affordable, and evidence-based for underserved communities.

How does RNM maintain high standards of safety, precision, and patient-centric care in advanced nuclear medicine therapies?

From the very beginning, I focused on building strong systems, standardized protocols, and a culture of quality-driven healthcare. At RNM, we follow strict radiation safety measures, meticulous documentation processes, and carefully designed treatment workflows to ensure patient safety and accuracy. We are NABH accredited, which reflects our commitment to maintaining high healthcare standards. I personally believe that precision medicine requires teamwork, discipline, and ethical practice at every level. Most importantly, we have created a “patient first always” culture, where every member of the team understands the importance of empathy, transparency, and personalized care throughout the treatment journey.

What initiatives are you taking to spread awareness about theranostics and precision-based cancer care in India?

Awareness remains one of the biggest challenges in nuclear medicine because many patients and healthcare professionals are still unfamiliar with theranostics and molecular imaging. At RNM, I actively work with clinicians, hospitals, and patient communities to improve awareness about precision oncology and the importance of early PET-CT imaging. We regularly participate in workshops, academic discussions, and collaborative initiatives to educate the larger medical community about targeted radionuclide therapies. My goal is not only to provide treatment but also to contribute toward building a stronger ecosystem for precision medicine in India, where advanced oncology care becomes more widely understood and accessible.

How do you balance advanced medical technology with compassion and personalized patient care?

For me, technology and compassion are not separate; they complement each other. I believe innovation only has value when it genuinely improves patient care and quality of life. At RNM, every clinical decision is made in the patient’s best interest. If a simpler or more affordable treatment can provide the same outcome, I openly recommend that option. Cancer treatment is emotionally overwhelming, so beyond advanced diagnostics and therapies, we focus strongly on empathy, communication, and emotional support. I believe trust is built when patients feel heard, respected, and confident that their treatment decisions are being guided ethically and transparently.

What is your long-term vision for RNM Theranostic Center and the future of precision oncology in India?

My long-term vision is to contribute toward building a stronger ecosystem for precision medicine and nuclear oncology in India. I want RNM to grow not only as a clini­cal center but also as a platform for research, innovation, and collaboration in theranostics. We are already ex­ploring initiatives involving artificial intelligence, data standardization, and advanced molecular imaging to improve diagnostics and prognostic assessment. I also hope to strengthen collaborations with academic and in­ternational institutions to bring newer therapies and re­search opportunities to India. I strongly believe India has the potential to become a global leader in theranostics and precision oncology in the coming years.

Parveen Kundu, Founder, RNM Theranostic Center

Parveen Kundu is the Founder of RNM Theranos­tic Center and a specialist in nuclear medicine and precision oncology. An alumnus of All India Institute of Medical Sciences and Postgraduate Institute of Medical Education and Research, she is dedicated to expanding access to advanced theranostic imaging and radionuclide therapies across underserved re­gions in India.